Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta

Authors Castrop F, Haslinger B, Hemmer B, Buck D

Received 3 June 2013

Accepted for publication 10 July 2013

Published 16 September 2013 Volume 2013:9 Pages 1339—1349


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Florian Castrop, Bernhard Haslinger, Bernhard Hemmer, Dorothea Buck

Department of Neurology, Technische Universität München, Munich, Germany

Abstract: Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequently in young adulthood when productivity is usually highest; it is of chronic nature and, in the majority of patients, it will result in accumulation of disability. Due to loss of productivity in patients and caregivers as well as high expenses for medical treatment, MS is considered a disease with high economic burden for patients and society. Several drugs have been approved for treatment of MS. While treatment ameliorates the course of the disease, it is very costly; therefore, pharmacoeconomics, evaluating costs and effects of disease-modifying treatment in MS, has become an important issue. Here, we review the economic impact and treatment strategies of MS and discuss recent studies on pharmacoeconomics of early treatment with interferon beta.

Keywords: MS, pharmacoeconomics, disease-modifying therapy, interferon beta, CIS

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.